Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 8, 2019

Janssen files for European authorisation of Ebola vaccine

Johnson & Johnson subsidiary Janssen Pharmaceutical has filed marketing authorisation applications (MAAs) with the European Medicines Agency (EMA) for the approval of an Ebola vaccine regimen.

Johnson & Johnson subsidiary Janssen Pharmaceutical has filed marketing authorisation applications (MAAs) with the European Medicines Agency (EMA) for the approval of an Ebola vaccine regimen.

The two-dose regimen is intended to prevent Ebola virus disease (EVD) caused by Zaire ebolavirus species. Janssen submitted two MAAs for each vaccine in the regimen.

Based on Janssen’s AdVac technology, Ad26.ZEBOV is the first dose of the Ebola vaccine regimen. The second MVA-BN-Filo dose is based on MVA-BN technology from Bavarian Nordic.

The doses are to be administered approximately eight weeks apart.

For the vaccine regimen, adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) are genetically modified to prevent replication in human cells.

The vectors are also modified to generate one of the Ebola virus proteins to induce an immune response.

In the MAAs, Janssen included results from Phase I, II and III clinical trials, which were conducted to assess the safety and immunogenicity of the vaccine regimen in adults and children.

The applications are also supported by data from preclinical studies and immunobridging analyses.

More than 6,500 individuals in the US, Europe and Africa have participated in more than ten trials of the Ebola vaccine to date.

Janssen Pharmaceutica global therapeutic area head Johan Van Hoof said: “Our goal is to deliver a vaccine that can be used both in response to Ebola outbreaks and also more proactively as a prophylactic tool to help countries protect their populations.”

This September, EMA’s Committee for Medicinal Products for Human Use (CHMP) awarded an accelerated assessment for the MAAs.

Janssen is in discussions with the US Food and Drug Administration (FDA) about the data set necessary to seek approval for its vaccine regimen.

The company also partnered with the World Health Organization (WHO) to register the product in African markets.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU